Biogen Hemo Therapy Travels 'A-LONG' Pathway to Success
Last fall, when Biogen Idec Inc. and partner Swedish Orphan Biovitrum made public the Phase III from A-LONG, a trial testing their long-lasting recombinant factor VIII candidate – since branded Eloctate – in hemophilia A, most analysts were pleased but cautious.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter